Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry

Fig. 2

Mortality and survival analyze depending on gender and pirfenidone treatment. a No statistically significant higher mortality was observed in males (HR 1.5; 95% 0.94–2.3, p = 0.092). b There was no statistically significant difference in mortality among pirfenidone treated patients depending on gender (HR 1.6; 95% 0.86–3, p = 0.139. c Survival time (weeks) analyzed by gender and pirfenidone treatment was not statistically different

Back to article page